지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 580 - 586 (7page)
이용수
초록· 키워드
오류제보하기
Purpose: Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastaticcastration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy (ADT) before diagnosis ofCRPC. We investigated the clinical efficacy of abiraterone acetate according to the duration of ADT. Materials and Methods: We reviewed the medical records of 20 patients with mCRPC who received abiraterone acetate afterfailure of docetaxel chemotherapy from May 2012 to March 2014 at Seoul National University Bundang Hospital. Clinical factorsincluding prostate-specific antigen (PSA) nadir level, time to PSA nadir, PSA doubling time, PSA response, and modes of progression(PSA, radiologic, clinical) were analyzed. Disease progression was classified according to the Prostate Cancer Working Group 2criteria. Results: The mean age and PSA value of the entire cohort were 76.0±7.2 years and 158.8±237.9 ng/mL, respectively. The medianfollow-up duration was 13.4±6.7 months. There were no statistically significant differences in clinical characteristics between patientswho received abiraterone acetate with ADT duration<35 months and those who received abiraterone acetate with ADT duration≥35 months. There were also no significant differences in terms of PSA progression-free survival, radiologic progression-freesurvival, and clinical progression-free survival between patients with ADT duration<35 months and those with ADT duration ≥35months. Conclusions: Although this was a retrospective study with a small sample size, we did not observe any statistically significant differencesin the clinical response to abiraterone acetate between mCRPC patients with long ADT duration and those with short ADTduration in terms of disease progression-free survival.
목차
등록된 정보가 없습니다.
참고문헌 (18)
참고문헌 신청
Agarwal N / 2012 / Novel molecular targets for the therapy of castration-resistant prostate cancer / Eur Urol 61:950~960
Heidenreich A / 2014 / EAU guidelines on prostate cancer. Part II:Treatment of advanced, relapsing, and castration-resistant prostate cancer / Eur Urol 65:467~479
Small EJ / 2006 / Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer / J Clin Oncol 24:3089~3094
Croke J / 2012 / Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review / BMJ Case Rep
Bahl A / 2013 / Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial / Ann Oncol 24:2402~2408
Heidenreich A / 2014 / EAU guidelines on prostate cancer. Part II:Treatment of advanced, relapsing, and castration-resistant prostate cancer / Eur Urol 65:467~479
Small EJ / 2006 / Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer / J Clin Oncol 24:3089~3094
Croke J / 2012 / Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review / BMJ Case Rep
Bahl A / 2013 / Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial / Ann Oncol 24:2402~2408
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaive patients with metastatic castration-resistant prostate cancer
Investigative and Clinical Urology
2022 .09
-
Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
Yonsei Medical Journal
2020 .01
-
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
Investigative and Clinical Urology
2019 .01
-
Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
Clinical Hypertension
2019 .01
-
Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population
Cancer Research and Treatment
2020 .01
-
Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
Radiation oncology journal : ROJ
2017 .01
-
The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
International Neurourology Journal
2016 .12
-
Relationship between Androgen Deprivation Therapy and Normal-Tension Glaucoma in Patients with Prostate Cancer: A Nationwide Cohort Study
Yonsei Medical Journal
2022 .10
-
Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
Yonsei Medical Journal
2015 .01
-
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
Yonsei Medical Journal
2016 .01
-
Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial
Investigative and Clinical Urology
2017 .01
-
Metabolic effects of androgen deprivation therapy
Investigative and Clinical Urology
2015 .01
-
전립선의 염증반응과 전립선특이항원의 변화
Urogenital Tract Infection
2015 .01
-
재발성 전립선암 환자에서 낮은 전립성특이항원을 보인폐전이 1예
대한내과학회지
2015 .01
-
Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database
Cancer Research and Treatment
2019 .01
-
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Investigative and Clinical Urology
2021 .11
-
Multicenter Comparison of Four Automated Immunoassay Analyzers for Prostate Specific Antigen
Annals of Laboratory Medicine
2019 .01
-
Prostate Cancer Screening in the Fit Chilean Elderly: a Head to Head Comparison of Total Serum PSA versus Age Adjusted PSA versus Primary Circulating Prostate Cells to Detect Prostate Cancer at Initial Biopsy
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Cancer Research and Treatment
2022 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0